SecBot SecBot
SECBOTREPLAY Home › Report › AEON

AEON · IND submission for ABP-450

AEON Biopharma Inc · PRESS-RELEASE filed Nov 9, 2026 at 08:00 ET

At the news

NEUTRALIMPACT 4/10

PRESS-RELEASE filed Nov 9, 2026 at 08:00 ET

AEON Biopharma submitted an IND to the FDA for a CMAP pharmacodynamic study of its ABP-450 biosimilar to BOTOX, following a recent Type 2b meeting. The study is designed to generate comparative evidence of neuromuscular activity, with initiation expected in Q1 2027. The filing is a procedural milestone in the biosimilar development pathway, with no financial data or regulatory decision announced.

  • AEON submitted an IND for a CMAP pharmacodynamic study comparing ABP-450 to BOTOX.
  • The submission follows a Biosimilar Biological Product Development Type 2b meeting with the FDA.
  • Study initiation expected in Q1 2027.
  • AEON is pursuing a 351(k) biosimilar pathway with a totality-of-evidence strategy that may avoid a standalone comparative efficacy study.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access